International audienceAbstractBackgroundDespite international initiatives like Orphanet, it remains difficult to find up-to-date information about rare diseases. The aim of this study is to propose an exhaustive set of queries for PubMed based on terminological knowledge and to evaluate it versus the queries based on expertise provided by the most frequently used resource in Europe: Orphanet.MethodsFour rare disease terminologies (MeSH, OMIM, HPO and HRDO) were manually mapped to each other permitting the automatic creation of expended terminological queries for rare diseases. For 30 rare diseases, 30 citations retrieved by Orphanet expert query and/or query based on terminological knowledge were assessed for relevance by two independent re...
Background: The web has become a primary information resource about ill-nesses and treatments for bo...
Background: Rare disease information sources are incom-pletely and inconsistently cross-referenced t...
JALE has received funds from Instituto de Salud Carlos III (Grant# PI20-1126), CIBERER (Grant# PIT21...
International audienceAbstractBackgroundDespite international initiatives like Orphanet, it remains ...
International audienceIntroductionEstimating the prevalence of diseases is crucial for the organizat...
Rare disease patients too often face common problems, including the lack of access to correct diagno...
AbstractBackgroundAt present, there is no universal definition of rare disease.ObjectiveTo provide a...
International audienceClinical practice guidelines (CPGs) for rare diseases (RDs) are scarce, may be...
Clinical practice guidelines (CPGs) for rare diseases (RDs) are scarce, may be difficult to identify...
Abstract Background Existing resources to assist the diagnosis of rare diseases are usually curated ...
Abstract Objectives The aims of this paper is to search and explore publications in the field of pha...
Between 2000 and 2021, the European Medicines Agency (EMA) assigned the orphan designation to over 1...
Background: Rare diseases are individually rare but globally affect around 6% of the population, and...
Purpose Recognizing rare diseases (RDs) and initiating appropriate investigation an...
AbstractRare diseases are those with a particularly low prevalence; in Europe, diseases are consider...
Background: The web has become a primary information resource about ill-nesses and treatments for bo...
Background: Rare disease information sources are incom-pletely and inconsistently cross-referenced t...
JALE has received funds from Instituto de Salud Carlos III (Grant# PI20-1126), CIBERER (Grant# PIT21...
International audienceAbstractBackgroundDespite international initiatives like Orphanet, it remains ...
International audienceIntroductionEstimating the prevalence of diseases is crucial for the organizat...
Rare disease patients too often face common problems, including the lack of access to correct diagno...
AbstractBackgroundAt present, there is no universal definition of rare disease.ObjectiveTo provide a...
International audienceClinical practice guidelines (CPGs) for rare diseases (RDs) are scarce, may be...
Clinical practice guidelines (CPGs) for rare diseases (RDs) are scarce, may be difficult to identify...
Abstract Background Existing resources to assist the diagnosis of rare diseases are usually curated ...
Abstract Objectives The aims of this paper is to search and explore publications in the field of pha...
Between 2000 and 2021, the European Medicines Agency (EMA) assigned the orphan designation to over 1...
Background: Rare diseases are individually rare but globally affect around 6% of the population, and...
Purpose Recognizing rare diseases (RDs) and initiating appropriate investigation an...
AbstractRare diseases are those with a particularly low prevalence; in Europe, diseases are consider...
Background: The web has become a primary information resource about ill-nesses and treatments for bo...
Background: Rare disease information sources are incom-pletely and inconsistently cross-referenced t...
JALE has received funds from Instituto de Salud Carlos III (Grant# PI20-1126), CIBERER (Grant# PIT21...